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S U M M A R Y 
The determination of anti-HBs as a screening test before vaccination has been 
advisable in order to encounter immune individuals that don't need to receive 
vaccine protection. A case-report is presented and three other cases are reviewed 
from the literature. Anti-HBs was positive in these health-care personnels that 
developped typical acute B hepatitis. Different subtyping involving the d/y de-
terminants were found in the first case, but false-positive anti-HBs even with 
high titres, determined by RIA, were found in the other cases. Concomitant de-
termination of anti-HBc or absence of screening tests seem to be more reasona-
ble policies until a low-cost and risk-free vaccine is produced. 
I N T R O D U C T I O N 
Hepatitis B is a widespread infection all 
over the world. Hospital personnels as well as 
drug addicts and male homosexuals are the 
most important groups with the higher risk of 
getting the infection. This high risk population, 
more frequently in contact with the B virus, 
can develop a subclinical infection, which would 
naturally protect them against hepatitis B. Fol-
lowing this reasoning and taking in account 
that B vaccine, made up of human serum, is 
expensive and not entirely free of eventual de-
sease transmission, the determination of anti-
HBs as a screening test pre-vaccination would 
be advisable, and has been recomended by 
many Authors ?. 8. 
Herein a case report of a physician who al-
ready had anti-HBs in the serum and developed 
an acute B hepatitis is described. 
CASE REPORT 
E.S., female, 40 years old, physician. The 
first determination of virus B markers was 
made in April 1981 during a research screening 
in hospital personnel 1 2 and at that time her se-
rum was positive for anti-HBs. Contamination 
occurred in the seventeenth of March 1983, by 
needle stick, while taking blood sample from 
a HBsAg positive and also HBeAg positive pa-
tient with persistent chronic hepatitis. Preven-
tive measures, such as pos-exposure vaccination 
or administration of hyperimmune gammaglo-
bulin, were not carried out. In the 23rd of June 
symptoms of dizziness and weakness appeared, 
being associated with coluria in the 28th, when 
blood samples were taken for transaminases 
determinations. As they were above 10 times 
the upper normal limit a diagnosis of acute he-
patitis was made and serum taken for viral 
markers determinations. 
Symptoms persisted and worsened in the 
following weeks with deep jaundice, intense 
anorexia and weight loss. Liver was palpable 
2 cm bellow the right costal margin, but spleen 
was not detectable. Sequential laboratorial data 
are summarized in Table I and Graphic 1 illus-
trates the evolution of main parameters. 
Complete recovery with negativation of the 
HBsAg was achieved after 12 weeks and one 
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year after (August/84) biochemical examina­
tions re-assured this recovery. Virus B markers, 
determined by Enzymeimmunoassay (ELISA) , 
showed HBsAg negative and both anti-HBs and 
anti-HBc positive. Re-testing the serum taken 
at the onset of acute hepatitis the anti-HBs 
remained positive by RIA but it turned to be 
negative by ELISA. 
COMMENTS 
It is well known that in the course of a ty­
pical virus B hepatitis the positivity of anti-
HBc indicates present infection whereas the de­
velopment of anti-HBs, after 8 to 12 weeks, is 
the usual resolution of the disease. This de­
velopment means not only cure but also natural 
immunological prevention against new exposu­
res to the virus. 
The vaccine, prepared from the serum of 
hepatitis B carriers and having only surface 
antigen (HBsAg) with no Dane particles, will 
provide the formation of anti-HBs and this sur­
face antibody protects against the disease. Al­
though subtypes of virus B have been describ­
ed, cross protection was also demonstrated 
after vaccination I 3. 
Based on these facts, simultaneous occur­
rence of HBsAg and anti-HBs should never 
happen. Nevertheless this concomitance has 
been reported 1,3,5,10,14,15. i n the earlier re­
ports 5, 10 five cases out of seven were blood-
donors apparently healthy while the other two 
were sick patients; one in hemodialysis and the 
other with chronic active hepatitis. These Au­
thors subtyped both anti-HBs and HBsAg point­
ing out that the paradoxal combination involved 
the d/y system of determinants. At that time 
they formulated two hypothesis trying to ex­
plain these findings. In the first one, a infec­
tion with one subtype develops a tolerant car­
rier state which is followed by another infec­
tion with a different subtype eliciting an immu­
ne response. In the second one, a vertical 
transmission in early life could lead to a tole­
rance to HBsAg of a particular subtype and a 
re-infection by another subtype would develop 
immunological reaction with the appearance of 
anti-HBs. In Foutch's series 3 the antibody has 
never appeared before the antigen. Although 
clinical data about all the patients are not avai­
lable in these laboratory investigations, it was 
shown that seven of the 13 patients had renal 
diseases, six of whom in hemodialysis. TA­
BOR 1 4 describes a chronic HBsAg carrier and a 
Kaposi's sarcoma among his three patients and 
the reported case of BALAQUE 1 had a multi-
systemic disease. Besides the conclusion that 
anti-HBs can coexist with HBsAg, these re­
ports support the possibility of an atypical 
immunological response to hepatitis B virus, 
with monotypic anti-HBs failing to protect 
against infection by a different subtype. If this 
happens only in persons with peculiar immu­
nological responses, suffering from renal or 
other diseases is still to be demonstrated. 
A different situation is herein reported. In 
this case report, as in three others of the lite­
rature "An, the antibody and not the antigen 
was detected from eight months to three years 
before the exposition to hepatitis B virus had 
occurred. Although aware of the risk of acquir­
ing hepatitis by needle stick, the three hospital 
personnels did not take preventive measures 
believing that the anti-HBs in their serum indi­
cated that they were immune against B hepa­
titis. Table I I summarizes the main data from 
the three cases reported and includes the one 
herein described as the fourth. 
The first case-report4 was published in 
1976, still using passive hemagglutination for 
thj detection of antiHBs. No effect on anti-y 
reagent was demonstrated when the 8 catego­
ries of this antibody were subtyped in the se­
rum taken before the acute B infection. This 
anti-y reaction appeared in the serum after cli­
nical hepatitis. The two other cases were men­
tioned in letters to the editors while discussing 
screening before vaccination for B hepatitis. 
They are more recent cases and anti-HBs de­
terminations were made by RIA. As a common 
feature, these two cases and the first one were 
negative for anti-HBc (the core antibody of B 
hepatitis). In the case-report of SHERERTZ & 
HOOFNAGLE» the antiHBs was not blocked 
by any of the eight known subtypes of HBsAg 
but only by dithiothreitol, while L I N N E M A N N 
& A S K E Y « suggested that the anti-HBs of their 
case was probably IgM. 
Low-titre of anti-HBs, defined as a ratio 
less than 10 times the cutt-off when radioimmu­
noassay is used, could account for false-positive 
reactions. Nevertheless, high titre Anti-HBs 
were observed in the third case-report proving 
that titring alone is not safe. 
In this case-report, before determining sub-
types, it was decided to re-test the serum sam-
ples for anti-HBs by another sensitive method, 
ELISA, and surprisingly the result was negative. 
Such fact would support two possibilities: a) 
the positivity by RIA was a false-positive reac-
tion; b) the negativity by ELISA was due to 
less sensibility of this method. Studies from the 
literature 9 are not in favor of this second hy-
pothesis, showing equal sensibility for RIA and 
ELISA. 
Finally we should say that, although rare, 
false-positive anti-HBs or monotypic non-protec-
tive anti-HBs have been described when screen-
ing before hepatitis B vaccination. The policy 
of screening only for anti-HBs, in order to con-
sider people from high risk groups as immune, 
should be seriously questioned. Associated po-
sitivity of anti-HBc seems to indicate real im-
munity and is easier to be performed than the 
"specificity testing" for anti-HBs, as proposed 
by FIEDLER 2 . The determination of the three 
markers (anti-HBs, anti-HBc and HBsAg) besi-
des being more expensive, can be refused by 
some physicians and healthy-care workers. A 
practical alternative is not to screen at all, even 
with the possibility of administrating the vacci-
ne to some immune persons and to assympto-
matic carriers. But this policy is also expensi-
ve and cost effectiviness should be calculated, 
since we still have a blood-borne first genera-
tion vaccine. We hope technological advances 
in the near future will permit low-cost and 
free-risk vaccinations for B virus hepatitis. 
RESUMO 
Hepatite aguda B em paciente previamente po-
sitiva para o anticorpo de superfície (anti-HBs) 
determinado por radioimunoensaio. Relato de 
caso e revisão da literatura 
A determinação do anticorpo de superfície 
contra a hepatite B (anti-HBs) precedendo a va-
cinação tem sido aconselhada com o intuito de 
encontrar indivíduos já imunes, para os quais 
esta administração seria desnecessária. 
Um caso clínico é aqui apresentado, jun-
tamente com a revisão de três casos menciona-
dos na literatura, nos quais o anti-HBs foi po-
sitivo em pessoal hospitalar, o que justificou 
sua não vacinação e ausência de medidas pre-
ventivas face contaminação pelo vírus B. Mal-
grado esta aparente proteção pela presença do 
anti-HBs eles desenvolveram hepatite aguda tí-
pica pelo vírus B. 
No primeiro caso da literatura a subtipa¬ 
gem revelou que o anti-HBs do passado e a in-
fecção atual tinham determinantes d/y diferen-
tes. Entretanto, os outros casos relatados mos-
travam ser o anti-HBs, dosado por radioimu-
noensaio ( R I E ) , um falso positivo. Em nosso 
relato de caso o soro colhido no início da hepa-
tite aguda foi re-testado por dois métodos di-
ferentes e igualmente sensíveis. Observou-se 
persistência de positividade pelo RIE porém 
negatividade pelo enzimaimunoensaio (ELISA) 
A determinação concomitante de anti-HBs 
e anti-HBc ou ainda dos três marcadores é uma 
das alternativas propostas, enquanto que outra 
conduta seria a não realização de qualquer tes-
te pré-vacinação. Acreditamos que o desenvol-
vimento tecnológico propiciará produção de va-
cinas menos dispendiosas e totalmente isentas 
de risco em futuro próximo. 
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